ArticleCancer biology & therapy2025
Validation of the important role and prognostic value of KIF14 in triple-negative breast cancer.
Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis and limited treatment options. Elevated Kinesin Family Member 14 (KIF14) expression in breast cancer (BC) is correlated with poor prognosis, but its role in TNBC remains unclear.
methodsKIF14 expression was analyzed using TCGA, TIMER, and GEO databases, and its association with prognosis was assessed via Kaplan‒Meier plotter. Functional assays, including CCK-8, wound healing, and Transwell assays, were performed to evaluate KIF14's impact on TNBC cell proliferation, migration, and invasion. GO and KEGG analyses of transcriptome data were used to explore molecular mechanisms. The relationship between KIF14 expression and immune infiltration was assessed in the TIMER database. KIF14 expression in clinical samples was validated using qRT-PCR and immunohistochemistry, and its correlation with clinical features was examined.
resultsKIF14 was significantly upregulated in BC (
conclusionKIF14 promotes TNBC progression and serves as a potential diagnostic and prognostic biomarker for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.